WO2018150395A4 - 4-n-butylresorcinol preparations - Google Patents
4-n-butylresorcinol preparations Download PDFInfo
- Publication number
- WO2018150395A4 WO2018150395A4 PCT/IB2018/052742 IB2018052742W WO2018150395A4 WO 2018150395 A4 WO2018150395 A4 WO 2018150395A4 IB 2018052742 W IB2018052742 W IB 2018052742W WO 2018150395 A4 WO2018150395 A4 WO 2018150395A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- butylresorcinol
- formulation
- skin
- agents
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
A medical or cosmetic formulation such as pastes, gels, lotions, serums, creams, peels and sprays comprising 4-n-butylresorcinol in a concentration greater than substantially 18% preferably between substantially 20% and substantially 60% diluted with a hydrophilic agent, or any diluent known in the art, can be used for treating various skin conditions, e.g. complexion, hyperpigmentation, melasma, pore size, skin density, hydration, superficial scars, post-operative scars, hypertrophic and atrophic scars, post-inflammatory hyperpigmentation, solar lentigines, acne vulgaris and as an anti-aging treatment. The formulae include peels and skincare using various delivery systems, such as liposomal delivery systems and all agents to aide penetration of the epidermis, known in the art. Compositions may include preservatives, such as levulinic acid. Formulation embodiments of the invention can have any one or more of the following features: • Said formulation is between substantially 18% and substantially 60% • Said concentration to produce a skincare treatment • Said concentration to produce a mild peel • Said concentration to produce a medium peel • Said concentration to produce a deep peel • For use in the treatment of any or more of the group comprising: complexion, anti-aging, hyperpigmentation skin disorders, atrophic and hypertrophic superficial and post-operative scars, hydration, skin density, pore size, acne vulgaris • Comprising any one or more of the ingredients mentioned herein for the treatment of melasma • Comprising any one or more of the ingredients mentioned herein for the treatment of hyperpigmentory skin disorders • Another aspect of the invention consists in a method of treating the skin, in which there is used a formulation embodying the invention • A formulation consisting any one of the following: DMSO, levulinic acid, fatty acids such as oleic acid, coconut oil, sources of vitamin C, e.g. rosehip seed, camu camu, infection control such as natural antibiotics e.g. colloidal silver, hydration agents such as glycerin and hyaluronic acid, walnuts, opti zinc, inhibition of collagen synthesis, healing agents such as croton lechleri, tyrosine kinase inhibitors, calcium antagonists such as magnesium, antioxidants such as r lipoic acid, astaxanthin and ubiquinol coqlO, telomeres lengthening agents such as resveratrol and cycloastrogenol, TGF-b inhibitors, protein kinase C (PKC) inhibitors, scar reduction agents such as niacinamide, anti¬ inflammatories such as white willow bark, bamboo, cannabinoids, watermelon skin, agents for collagen stimulation, anti-glycation, immune pathways, red spinach, cherry blossom, tormentil, chitin, rambutan, amino acids, (GL1), (GL3), (TTG1), soursop, oleuropein, cassia, apple skin, osmanthus and all anti-aging agents known in the art. These additional components, may be combined with 4-n-butylresorcinol or may be used separately.
Claims
1. An exfoliating formulation comprising of 4 N Butylresorcinol for hyperpigmentory skin disorders.
2. An exfoliating formulation comprising of 4 N Butylresorcinol for scars.
3. An exfoliating formulation comprising of 4 N Butylresorcinol for acne.
4. An exfoliating formulation comprising of 4 N Butylresorcinol for the complexion i.e. whiten, pore size, skin density, skin firmness, elasticity, anti-glycation, skin barrier function and wrinkles.
5. A formulation as claimed in any preceding claim that peels the skin at varying depths.
6. A topical formulation comprising of 4 N Butylresorcinol for scars.
7. A topical formulation comprising of 4 N Butylresorcinol for acne.
8. A medical or cosmetic topical formulation comprising of 4 N Butylresorcinol in a
concentration greater than substantially 18% of total weight.
9. A medical or cosmetic topical formulation comprising of 4 N Butylresorcinol in a
concentration greater than substantially 20% of total weight.
10. A medical or cosmetic topical formulation comprising of 4 N Butylresorcinol in a
concentration between substantially 18% and 60% of total weight.
11. A medical or cosmetic exfoliating formulation comprising of 4 N Butylresorcinol in a
concentration greater than substantially 18% of total weight.
12. A medical or cosmetic exfoliating formulation comprising of 4 N Butylresorcinol in a
concentration greater than substantially 20% of total weight.
13. A medical or cosmetic exfoliating formulation comprising of 4 N Butylresorcinol in a
concentration between substantially 18% and 60% of total weight.
14. A medical or cosmetic exfoliating or topical formulation containing 4 N Butylresorcinol together with, resveratrol, curcumin, fucoidan, sulphur, white willow bark, ellagic acid, niacinamide and ferulic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909518.1A GB201909518D0 (en) | 2017-02-20 | 2018-04-20 | 4-N-Butylresorcinol preparations |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1702690.7 | 2017-02-20 | ||
| GB1702690.7A GB2562991A (en) | 2017-02-20 | 2017-02-20 | 4-N butylresorcinol in a skincare formulation in concentrations of twenty percent, up to and including sixty percent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2018150395A2 WO2018150395A2 (en) | 2018-08-23 |
| WO2018150395A3 WO2018150395A3 (en) | 2018-10-25 |
| WO2018150395A4 true WO2018150395A4 (en) | 2018-12-13 |
Family
ID=58486765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2018/052742 WO2018150395A2 (en) | 2017-02-20 | 2018-04-20 | 4-n-butylresorcinol preparations |
Country Status (2)
| Country | Link |
|---|---|
| GB (2) | GB2562991A (en) |
| WO (1) | WO2018150395A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109528730A (en) * | 2018-12-11 | 2019-03-29 | 江苏永健医药科技有限公司 | Application of the cycloastragenol in preparation prevention or Retinoids, Retin-A, Renova, Accutane |
| CN110227044A (en) * | 2019-05-12 | 2019-09-13 | 广州芊舟生物科技有限公司 | A kind of HA collagen stoste and preparation method thereof |
| CN110804453B (en) * | 2019-11-28 | 2020-08-04 | 中国海洋大学 | Method for reducing antibiotic resistance genes in soil by using wood vinegar and application |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001206813A (en) * | 2000-01-27 | 2001-07-31 | Pola Chem Ind Inc | Skin preparation for external use for physical therapy |
| DE102007038097A1 (en) * | 2007-08-13 | 2009-02-19 | Merck Patent Gmbh | tyrosinase |
| FR2946249B1 (en) * | 2009-06-05 | 2012-07-06 | Galderma Res & Dev | DEPIGMENTING TOPICAL COMPOSITIONS AND USES THEREOF. |
| FR2945442B1 (en) * | 2009-05-14 | 2012-08-03 | Fabre Pierre Dermo Cosmetique | USE OF DELTA-TOCOPHERYL-GLUCIDE AS DEPIGMENTING AGENT. |
-
2017
- 2017-02-20 GB GB1702690.7A patent/GB2562991A/en not_active Withdrawn
-
2018
- 2018-04-20 WO PCT/IB2018/052742 patent/WO2018150395A2/en active Application Filing
- 2018-04-20 GB GBGB1909518.1A patent/GB201909518D0/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018150395A2 (en) | 2018-08-23 |
| GB2562991A (en) | 2018-12-05 |
| WO2018150395A3 (en) | 2018-10-25 |
| GB201909518D0 (en) | 2019-08-14 |
| GB201702690D0 (en) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11426442B2 (en) | Compositions and methods for invasive and non-invasive procedural skincare | |
| Saha | Cosmeceuticals and herbal drugs: practical uses | |
| US9000049B2 (en) | Combination of lycopene, polyphenol, and vitamins for the care of keratin materials | |
| WO2018150395A4 (en) | 4-n-butylresorcinol preparations | |
| CA2899814A1 (en) | Methods of skin whitening by use of canola extracts | |
| US20160074353A1 (en) | Use of petroselinic acid to fight against aesthetic disorders of the body figure | |
| KR20170038581A (en) | Composition containing aha, urea, and niacinamide for softening and whitening stratum corneum | |
| WO2014030117A4 (en) | Cosmetic use of the essential oil of laserpitium siler l. against the signs of aging of the skin and as a skin antioxidant | |
| KR102472978B1 (en) | Composition for improving skin | |
| KR20150087146A (en) | Composition for improving skin | |
| EP2819684A1 (en) | Use of starfruit extract as a cpt-1 modulator and compositions thereof | |
| US9682025B2 (en) | Combination of active agents for oral administration for improving the quality of nails | |
| KR20160114018A (en) | Composition for improving skin | |
| KR20170030836A (en) | External composition for antiaging comprising osthole | |
| Gupta | Party peels | |
| JP2014144929A (en) | Composition containing vitamins for preventing or treating acne | |
| Farrisa | Cosmeceuticals for Acne and Rosacea | |
| Lupo et al. | Cosmeceuticals for enhancing cosmetic procedures | |
| EP2854783B1 (en) | Mixture for the inhibition of melanin biosynthesis | |
| JP2007238588A (en) | Mixed cream for preventing and ameliorating beautiful skin effect, varicose vein of lower extremity and skin cancer | |
| Resnik | The role of priming the skin for peels | |
| Yang et al. | The efficacy and safety of a 70% glycolic acid peel with vitamin C for the treatment of photoaging | |
| Talakoub et al. | Antiaging Cosmeceuticals | |
| Glass | of Skin Rejuvenation by Nonprescription Topical Therapy | |
| KR102397975B1 (en) | External composition for moisturizing of skin comprising kirenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18737972 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2018737972 Country of ref document: EP Effective date: 20190920 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18737972 Country of ref document: EP Kind code of ref document: A2 |